<DOC>
	<DOCNO>NCT01655823</DOCNO>
	<brief_summary>Chemotherapy-induced peripheral neuropathy ( CIPN ) major dose-limiting side effect many chemotherapeutic agent include vincristine , paclitaxel , cisplatin , oxaliplatin , bortezomib ixabepilone . Chemotherapy-induced peripheral neuropathy commonly occur great 40 % patient . To improve peripheral neuropathy , chemotherapy dose often either decrease discontinue potentially affect tumor responsiveness , prognosis , survival . There unmet medical need treatment cancer patient chemotherapy induced neuropathic pain ( CINP ) propose study investigate efficacy safety multiple dose level tetrodotoxin ( TTX ) versus placebo moderate severe neuropathic pain cause chemotherapy .</brief_summary>
	<brief_title>The Purpose This Study Determine Tetrodotoxin ( TTX ) Effective Treatment Pain Resulting From Chemotherapy Treatment</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Tetrodotoxin</mesh_term>
	<criteria>If female , childbearing potential . Patients document neuropathic pain Cancer Patients complete chemotherapy regimen include taxanes platinum ( ) evidence actively progressive disease . Concurrent hormonal therapy allow Patients stable moderate severe neuropathic pain Patients Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 1 . Patients able complete studyrelated questionnaire independently either English Spanish . History peripheral neuropathy attribute cause chemotherapy . Patients receive concurrent agent know cause peripheral neuropathy within 30 day Randomization . Current use therapy ( y ) , include `` alternative '' therapy , treatment peripheral neuropathy within 30 day Randomization ( exception protocol allow concurrent medication ) . Patients use controlled release opioids within seven day baseline period expect use control release opioids time baseline end study . Patients abnormal kidney function . Patients bone metastasis . Patients scheduled treatment cancer chemotherapy radiotherapy screen end study visit . Current use lidocaine type antiarrhythmic drug within 30 day Randomization . Current use scopolamine acetylcholinesteraseinhibiting drug physostigmine within 30 day Randomization . Current cause Chemotherapy Induced Neuropathic Pain attribute Velcade ( Bortezomib ) vinca alkaloid analogue vincristine , vinblasine , vinorelbine vindesine . Current use tricyclic antidepressant medication , anticonvulsant monoamine oxidase inhibitor . Patients current uncontrolled asthma lung disease . Patients significant heart disease . Use investigational agent within 30 day prior screen schedule receive investigational drug TTX course study . Females pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Pain</keyword>
	<keyword>Puffer fish</keyword>
	<keyword>Tetrodotoxin</keyword>
	<keyword>TTX</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>WEX Pharmaceuticals</keyword>
</DOC>